SALT LAKE CITY, Aug. 16, 2021 /PRNewswire/ -- Recursion, a digital biology company industrializing drug discovery, today announced the appointment of Jordan Christensen as its Vice President of Engineering. In addition to leading all of Recursion's software engineering efforts, Christensen will act as the site leader at Recursion's new Toronto office, which is slated to open in fall 2021. Recursion aims to hire 50 people by the end of 2021 for its first multidisciplinary expansion and first expansion into Canada.
"I am thrilled to have Jordan join Recursion to scale our engineering teams and systems. Having robust and flexible data and machine learning systems is critical for us to succeed in our mission to industrialize drug discovery," said Recursion Chief Technology Officer Ben Mabey. "Jordan's experience building teams and reliable systems in various technology domains will be critical as we continue to grow rapidly and establish our new Toronto office."
Christensen comes to Recursion with 20 years of experience as a technology and product leader building and scaling big data solutions, internet software, web platforms and collaborative teams. Christensen most recently served as the Vice President of Technology at ecobee in Toronto. His prior experiences include serving as the Head of Engineering and Data at WattPad, having previously held the position of Head of Data Products, and notably, as a founding team member at Kobo, a global leader in eReading.
"Recursion's commitment to Toronto really reinforces its position as a world leader in software and AI," said Jordan Christensen. "I've been inspired by the culture and mission at Recursion, and I can't wait to join the team and help them pursue their goals."
At Recursion, Christensen will lead and grow the engineering team across Toronto and Salt Lake City as the company continues to scale its drug discovery platform. The Toronto office will also be a focal point for Recursion's expanding digital chemistry efforts. Christensen's broad experience in the tech sector and his deep commitment to building inclusive work environments lay the groundwork for rapid growth in the Toronto office. Recursion plans to open the doors of its new hub in the fall with hires across the disciplines of data science, machine learning, engineering and computational biology.
About Recursion Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering. Our goal is to radically improve the lives of patients and industrialize drug discovery. Central to our mission is the Recursion Operating System, which combines an advanced infrastructure layer to generate what we believe is one of the world's largest and fastest-growing proprietary biological and chemical datasets. We combine that with the Recursion Map, a suite of custom software, algorithms and machine learning tools that we use to explore foundational biology unconstrained by human bias and navigate to new biological insights. Learn more at www.Recursion.com, or connect on Twitter and LinkedIn.
Forward-Looking Statements This document contains information that includes or is based upon "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including, without limitation, those regarding. Recursion's mission; research and development activities; plans with respect to preclinical, clinical, and late discovery programs; collaborations; prospective products and their anticipated future applications or performance; platform; technology; facilities expansion; growth; expenses; our ability to obtain, maintain and enforce intellectual property and cybersecurity protections, and business and financial performance; and all other statements that are not historical facts. Forward-looking statements may or may not include identifying words such as "plan," "will," "expect," "anticipate," "intend," "believe," "potential," "continue," "target," and similar terms. These statements and their underlying assumptions are subject to known or unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include, but are not limited to challenges inherent in pharmaceutical research and development, including the timing and results of preclinical and clinical programs, where the risk of failure remains high and failure can unexpectedly occur at any stage prior to regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors; our ability to fund development activities and achieve development goals; the success of our collaboration activities; our ability to obtain regulatory approval of, and ultimately commercialize, drug candidates; the impact of the COVID-19 pandemic on our business, clinical trials, financial condition, and results of operations; our ability to obtain, maintain, and enforce intellectual property and cybersecurity protections; our ability to attract, motivate, and retain key employees; and other risks and uncertainties described under the heading "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including Recursion's Prospectus for our initial public offering filed on April 16, 2021 and our recent Quarterly Report on Form 10-Q. All forward-looking statements are based on management's current estimates, projections, and assumptions, and Recursion undertakes no obligation to correct or update any such statements, whether as a result of new information, future developments, or otherwise, except to the extent required by applicable law.